Population-Based Prognostic Factors for Survival in Patients With Burkitt Lymphoma

被引:47
作者
Castillo, Jorge J. [1 ]
Winer, Eric S. [1 ]
Olszewski, Adam J. [2 ]
机构
[1] Brown Univ, Rhode Isl Hosp, Div Hematol & Oncol, Alpert Med Sch,Miriam Hosp, Providence, RI 02903 USA
[2] Brown Univ, Div Hematol & Oncol, Alpert Med Sch, Mem Hosp Rhode Isl, Providence, RI 02912 USA
关键词
Burkitt lymphoma; prognostic factors; SEER; epidemiology; race; rituximab; B-CELL LYMPHOMA; ADULT BURKITT; RELATIVE SURVIVAL; CANCER REGISTRY; PLUS RITUXIMAB; CODOX-M/IVAC; CHEMOTHERAPY; THERAPY; CHOP; CHEMOIMMUNOTHERAPY;
D O I
10.1002/cncr.28264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDBurkitt lymphoma (BL) is an aggressive but potentially curable lymphoma, previously described in small, single-institution studies. This study evaluated prognostic factors for survival in adult patients with BL and a potential outcome improvement over the past decade in a population-based cohort. METHODSAdult patients with BL diagnosed between 1998 and 2009 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Prognostic factors were identified in a multivariate model for relative survival (RS), and trends in survival were evaluated using period analysis. RESULTSThe study cohort included 2284 patients, with a median age of 49 years and male predominance (2.6:1). Gastrointestinal tract and the head and neck were the most common sites of extranodal disease. Older age, black race/ethnicity, and advanced stage were associated with a worse survival. In the period analysis, trends in improved survival between 1998 and 2009 were seen, except for patients older than 60 years and black patients, whose survival did not improve. A prognostic score divided patients into 4 groups: low-risk (5-year RS: 71%), low-intermediate (5-year RS: 55%), high-intermediate (5-year RS: 41%), and high-risk (5-year RS: 29%; P <.001). CONCLUSIONSThe outcome of patients younger than 60 years with BL improved over the past decade. Age, race, and stage have a prognostic role for survival. The proposed score can help inform prognosis in newly diagnosed patients and stratify participants in future trials. Cancer 2013;119:3672-3679. (c) 2013 American Cancer Society.
引用
收藏
页码:3672 / 3679
页数:8
相关论文
共 35 条
[1]   Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models [J].
Andersson, Therese M. L. ;
Dickman, Paul W. ;
Eloranta, Sandra ;
Lambert, Paul C. .
BMC MEDICAL RESEARCH METHODOLOGY, 2011, 11
[2]  
[Anonymous], 2011, NAACCR GUID ENH HISP
[3]  
[Anonymous], 2013, SEER STAT SOFTW VERS
[4]   Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis [J].
Barnes, J. A. ;
LaCasce, A. S. ;
Feng, Y. ;
Toomey, C. E. ;
Neuberg, D. ;
Michaelson, J. S. ;
Hochberg, E. P. ;
Abramson, J. S. .
ANNALS OF ONCOLOGY, 2011, 22 (08) :1859-1864
[5]   COMBINED MODALITY THERAPY FOR ADULTS WITH SMALL NONCLEAVED CELL LYMPHOMA (BURKITTS AND NON-BURKITTS TYPES) [J].
BERNSTEIN, JI ;
COLEMAN, CN ;
STRICKLER, JG ;
DORFMAN, RF ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :847-858
[6]   Adult Burkitt leukemia and lymphoma [J].
Blum, KA ;
Lozanski, G ;
Byrd, JC .
BLOOD, 2004, 104 (10) :3009-3020
[7]   Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation computational realisation and applications [J].
Brenner, H ;
Gefeller, O ;
Hakulinen, T .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) :326-335
[8]   Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience [J].
Cairo, MS ;
Sposto, R ;
Perkins, SL ;
Meadows, AT ;
Hoover-Regan, ML ;
Anderson, JR ;
Siegel, SE ;
Lones, MA ;
Tedeschi-Blok, N ;
Kadin, ME ;
Kjeldsberg, CR ;
Wilson, JF ;
Sanger, W ;
Morris, E ;
Krailo, MD ;
Finlay, JL .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (04) :660-670
[9]   Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study [J].
Clarke, CA ;
Undurraga, DM ;
Harasty, PJ ;
Glaser, SL ;
Morton, LM ;
Holly, EA .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (04) :630-638
[10]   Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: Reliability of diagnosis and subtype classifications [J].
Clarke, CA ;
Glaser, SL ;
Dorfman, RF ;
Bracci, PM ;
Eberle, E ;
Holly, EA .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (01) :138-143